Schroder Investment Management Group Reduces Position in Alnylam Pharmaceuticals, Inc. $ALNY

Schroder Investment Management Group reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 69.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,580 shares of the biopharmaceutical company’s stock after selling 19,203 shares during the period. Schroder Investment Management Group’s holdings in Alnylam Pharmaceuticals were worth $2,798,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after buying an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after purchasing an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after purchasing an additional 185,783 shares during the last quarter. Geode Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 3.3% during the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $662,837,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 10,000 shares of the stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the transaction, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,517,119.43. This represents a 13.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 78,328 shares of company stock worth $35,705,793. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.6%

Shares of Alnylam Pharmaceuticals stock opened at $458.12 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The firm has a market cap of $60.52 billion, a price-to-earnings ratio of 1,908.83 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company’s 50-day simple moving average is $456.78 and its 200-day simple moving average is $402.24.

Wall Street Analyst Weigh In

ALNY has been the topic of several research analyst reports. Evercore ISI lifted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Bank of America boosted their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Oppenheimer restated an “outperform” rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. BMO Capital Markets boosted their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Finally, Truist Financial raised their target price on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $482.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.